Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Inclusion Criteria: 1. Age: 18-70. 2. Clinical stage Ⅱ-Ⅲ. 3. triple negative and invasive breast cancer confirmed by histopathology: Triple negative breast cancer is defined as: * negative for ER and PR (IHC nuclear staining \< 10%). * Her-2 negative (IHC 0,1 + without FISH, or IHC 2 + and without FISH amplification). 4. With clinically measurable focus: Measurable lesions observed on ultrasound, mammography, or magnetic resonance imaging (optional) within the month prior to randomization. 5. Organ and bone marrow function tests within 1 month before chemotherapy indicate no contraindications to chemotherapy: * neutrophils count absolute value ≥ 2.0×109/L * hemoglobin ≥ 100g/L * blood platelet ≥ 100×109/L * total bilirubin \< 1.5 ULN (upline of normal value) * creatinine \< 1.5×ULN * AST/ALT \< 1.5×ULN; 6. Cardiac ultrasound EF value ≥ 55%. 7. Females of childbearing age with negative serum pregnancy test 14 days before randomization. 8. ECOG score ≤1. 9. Sign informed consent. Exclusion Criteria: 1. Evidence of metastatic breast cancer (excluding metastatic breast cancer, a chest CT, abdominal ultrasound, or CT and bone scanning should be performed at any time point before diagnosis and randomization; PET/CT scanning can be used as an alternative imaging examination mean) . 2. The patients have received chemotherapy, endocrine therapy, targeted therapy, and radiation therapy for this disease. 3. The patient has a second primary malignant tumor, except for: \- Thoroughly treated skin cancer 4. Due to severe and uncontrollable other medical diseases, researchers believe the existence of chemotherapy contraindications.